miRecule, Inc.

miRecule, Inc. is focused on pioneering RNA-based therapeutics targeting cancer and muscular dystrophy, utilizing genomic data to personalize treatment for enhanced patient outcomes. Founded in 2016 and headquartered in Gaithersburg, US, miRecule, Inc. specializes in RNA therapeutics.

The company was co-founded by Anthony Saleh and Ashwin Kulkarni, with Saleh serving as the CEO. In May 2021, miRecule raised USD 5. 7 million in a SEED funding round, led by Alexandria Venture Investments, aiming to advance their therapeutic pipeline, particularly in head and neck cancer. miRecule™ is dedicated to developing RNA-based therapeutics aimed at cancer and muscular dystrophy by leveraging its proprietary DREAmiR™ platform.

Their focus is on individualizing treatment using genomic and outcome data, particularly targeting facioscapulohumeral muscular dystrophy (FSHD) through collaboration with Sanofi to create an innovative antibody-RNA conjugate. Their clients include healthcare providers, research institutions, and pharmaceutical partners primarily in North America and Europe. miRecule generates revenue through strategic collaborations that involve upfront and milestone payments based on development progress. Their flagship products, including the antibody-RNA conjugate for FSHD, are marketed directly to healthcare providers and through partnerships with larger pharmaceutical companies, allowing for a structured revenue stream aligned with the advancement of their therapeutic products.

Following the USD 5. 7 million SEED funding round raised in May 2021, miRecule will focus on advancing its microRNA therapy (MC-30) into clinical development for head and neck cancer. The company is exploring opportunities for expansion into additional therapeutic areas, leveraging its proprietary technologies, and aims to broaden its market presence in North America and Europe.